Latest news about Norris Medicines
Norris Medicines
16.30
-0.85(-4.96%)
Company Performance:
View Company Insights1D-4.96%
1M+4.22%
6M+22.10%
1Y+1.49%
5Y+59.49%
More news about Norris Medicines
14Feb 26
Norris Medicines Limited Announces Q3 FY26 Financial Results
Norris Medicines Limited's Board of Directors approved unaudited financial results for the quarter and year ended December 31, 2025, during a meeting held on February 14, 2026. The 30-minute board meeting was conducted in compliance with SEBI regulations, and the company plans to publish these results in newspapers as per regulatory requirements.
12Dec 25
Norris Medicines Independent Director Ms. Sathya Venkatachalam Resigns Due to Personal Reasons
Norris Medicines Limited announced the resignation of Independent Director Ms. Sathya Venkatachalam (DIN: 06970735) effective December 12, 2025, due to personal reasons. She also stepped down from all committee positions, including her role as Audit Committee Chairperson. The director confirmed no other material reasons for her departure beyond those stated.
12Dec 25
Norris Medicines Successfully Completes NAFDAC Regulatory Audit in Nigeria
Norris Medicines Limited successfully completed a regulatory audit by Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC) on December 9, 2025. The audit, which covered quality systems, manufacturing practices, documentation processes, and compliance parameters, resulted in no critical observations. This achievement strengthens the company's position in the Nigerian pharmaceutical market and validates its manufacturing capabilities against international standards.
11Dec 25
Bombay High Court Allows Norris Medicines' Criminal Appeal, Sets Aside ₹1.33 Crore Deposit Order
Norris Medicines Limited has won a significant legal victory with the Bombay High Court allowing Criminal Appeal No. 89 of 2020 and setting aside a deposit requirement of ₹1,32,92,359 plus 18% interest under the Maharashtra Protection of Interest of Depositors Act. The court ruled that since the related MPID Special Case No. 3 of 2003 resulted in acquittal, the original deposit order could not be sustained, rendering it infructuous and eliminating the financial obligation for the pharmaceutical company.
15Nov 25
Norris Medicines Reports Q2 FY26 Loss of Rs 102.86 Lakhs Amid Operational Challenges
Norris Medicines released unaudited financial results for Q2 FY2025-26, reporting a net loss of Rs 102.86 lakhs and revenue from operations of Rs 200.04 lakhs. The company's financial position shows strain with total assets at Rs 1,348.14 lakhs and negative other equity of Rs 2,582.19 lakhs, indicating significant accumulated losses. The Board of Directors approved these results on November 14, 2025, in compliance with SEBI regulations.
Industry Peers
Redington
MMTC
MSTC
Ravindra Energy
Vintage Coffee & Beverages
BN Agrochem
Creative Newtech
Elitecon International
TCC Concept
Pervasive Commodities
397.95
(-2.22%)
56.29
(-1.09%)
705.80
(-1.25%)
146.98
(-1.80%)
178.95
(-0.56%)
227.83
(+4.70%)
1,079.20
(-0.28%)
7.79
(-2.38%)
47.47
(-4.93%)
12.10
(+1.94%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
